ImmunoMind is a biotechnology platform that utilizes artificial intelligence to analyze multi-omics data for the design of personalized immunotherapies and vaccines, focusing on CAR-T cell therapies. The platform enhances therapy efficacy by predicting drug-immune system interactions and identifying biomarkers for patient stratification and monitoring.
Funding
$150K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing effective personalized immunotherapies and vaccines, particularly CAR-T cell therapies, is hindered by the complexity of drug-immune system interactions and the challenge of identifying predictive biomarkers. Analyzing multi-omics data to understand these interactions and stratify patients for optimal treatment response requires advanced computational tools and expertise.
Solution
ImmunoMind offers an open-source ecosystem that leverages artificial intelligence to analyze multi-omics data, facilitating the design of personalized immunotherapies and vaccines. The platform focuses on enhancing CAR-T cell therapy efficacy by predicting drug-immune system interactions and identifying biomarkers for patient stratification and monitoring. ImmunoMind enables users to compare cell population characteristics across different CAR-T products, evaluate CAR-T cell exhaustion, address CAR-T drug heterogeneity, and improve the CAR-T manufacturing process through cell differentiation insights. By providing these capabilities, ImmunoMind helps biotech startups de-risk immunotherapy development, assists biopharma companies in improving efficacy and patient stratification, and fuels discovery for research groups studying immune cell biology.
Target Audience
The primary users are biotech startups, immunotherapy biopharma companies, and research groups involved in developing personalized immunotherapies and vaccines, particularly CAR-T cell therapies.
Features
- AI-powered analysis of multi-omics data to predict drug-immune system interactions.
- Biomarker identification for patient stratification and monitoring in immunotherapy.
- Tools for comparing cell population characteristics across different CAR-T products.
- Evaluation of CAR-T cell exhaustion to improve product efficacy.
- Analysis of CAR-T drug heterogeneity to reduce toxicity.
- Insights into cell differentiation to optimize the CAR-T manufacturing process.
- Open-source ecosystem for personalized immunotherapy and vaccine design.